FDA Clearance Tracker · P890047-S070
PROVISC Ophthalmic Viscosurgical Device
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 4, 2026
Approved
Time to decision
158 days
Received Feb 27, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P890047-S070
- Device name
- PROVISC Ophthalmic Viscosurgical Device
- Applicant
- Alcon Research, Ltd.
- Applicant location
- Fort Worth, TX
- Received
- Feb 27, 2026
- Decided
- Aug 4, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P890047
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
An alternate manufacturing site at Alcon Fort Worth Manufacturing located at 6201 South Freeway, Fort Worth, Texas to perform the semiautomatic assembly of filled OVD (PROVISC, VISCOAT, and DUOVISC) syringes and components into blister packs, and packaging.
Source documents
Other decisions for Alcon Research, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular LensPMA supplement
P040020-S087 · Decided Aug 26, 2019 · 207 days after receipt · Panel Track
Device type: Lens, multifocal intraocular (MFK) · Ophthalmology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.